Abstract
The fluorescent carbon dot (C-dot) is a new class of carbon nanomaterials. It has a discrete or quasispherical structure, typically measures less than 10 nm and contains sp2/sp3 carbon, oxygen/nitrogen-based groups and surface-modified functional groups. Compared with semiconductor quantum dots (QDs), C-dots offer much lower toxicity and a better biocompatibility profile. Their other favorable features include easy and inexpensive synthesis and surface modification potential. C-dots can be morphologically classified into graphene-based quantum dots (GQDs) and amorphous carbon nanodots (ACNDs). Numerous methods have been developed to synthesize C-dots, and are mainly divided into ‘top-down’ and ‘bottom-up’ routes. In the top-down route, C-dots (mostly GQDs) is derived from the separation of large carbon precursors. The ‘bottom-up’ method primarily involves the dehydration, polymerization and carbonization of small molecules to form the GQDs and ACNDs through thermal/hydrothermal synthesis, microwave irradiation, and solution chemistry. Potential applications of C-dots have been explored in a number of cellular and in-vivo imaging approaches. However, some difficulties remain, including limited penetration depth and poorly controlled in-vivo pharmacokinetics, which depends on multiple factors such as the morphology, physiochemical properties, surface chemistry and formulation of C-dots. The exact mechanism of in-vivo biodistribution, cellular uptake and long-term toxicological effect of C-dots still need to be elucidated. An integrated multi-disciplinary approach involving chemists, pharmacologists, toxicologists, clinicians, and regulatory bodies at the early stage is essential to enable the clinical application of C-dots.
Keywords: Carbon Dots (C-dots), Photoluminescence (PL), Near-infrared (NIR), Quantum yield (QY), Optical Imaging, Iron oxide, Fe3O4.
Current Pharmaceutical Design
Title:Opportunities and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging
Volume: 21 Issue: 37
Author(s): Junqing Wang, Gang Liu, Ken Cham-Fai Leung, Romaric Loffroy, Pu-Xuan Lu and Yì Xiáng J. Wáng
Affiliation:
Keywords: Carbon Dots (C-dots), Photoluminescence (PL), Near-infrared (NIR), Quantum yield (QY), Optical Imaging, Iron oxide, Fe3O4.
Abstract: The fluorescent carbon dot (C-dot) is a new class of carbon nanomaterials. It has a discrete or quasispherical structure, typically measures less than 10 nm and contains sp2/sp3 carbon, oxygen/nitrogen-based groups and surface-modified functional groups. Compared with semiconductor quantum dots (QDs), C-dots offer much lower toxicity and a better biocompatibility profile. Their other favorable features include easy and inexpensive synthesis and surface modification potential. C-dots can be morphologically classified into graphene-based quantum dots (GQDs) and amorphous carbon nanodots (ACNDs). Numerous methods have been developed to synthesize C-dots, and are mainly divided into ‘top-down’ and ‘bottom-up’ routes. In the top-down route, C-dots (mostly GQDs) is derived from the separation of large carbon precursors. The ‘bottom-up’ method primarily involves the dehydration, polymerization and carbonization of small molecules to form the GQDs and ACNDs through thermal/hydrothermal synthesis, microwave irradiation, and solution chemistry. Potential applications of C-dots have been explored in a number of cellular and in-vivo imaging approaches. However, some difficulties remain, including limited penetration depth and poorly controlled in-vivo pharmacokinetics, which depends on multiple factors such as the morphology, physiochemical properties, surface chemistry and formulation of C-dots. The exact mechanism of in-vivo biodistribution, cellular uptake and long-term toxicological effect of C-dots still need to be elucidated. An integrated multi-disciplinary approach involving chemists, pharmacologists, toxicologists, clinicians, and regulatory bodies at the early stage is essential to enable the clinical application of C-dots.
Export Options
About this article
Cite this article as:
Wang Junqing, Liu Gang, Leung Cham-Fai Ken, Loffroy Romaric, Lu Pu-Xuan and J. Wáng Xiáng Yì, Opportunities and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging, Current Pharmaceutical Design 2015; 21 (37) . https://dx.doi.org/10.2174/1381612821666150917093232
DOI https://dx.doi.org/10.2174/1381612821666150917093232 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation
Inhibitors in Treatment of Inflammatory Diseases and
Cancer
Current Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery Purification and Characterization of a Novel Peroxidase from Bitter Gourd (Momordica charantia)
Protein & Peptide Letters Daphnane-Type Diterpene Orthoesters and their Biological Activities
Mini-Reviews in Medicinal Chemistry Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells
Current Molecular Medicine Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design Inorganic Nanoparticles for In Vitro Cancer Diagnosis: A Patent Review
Recent Patents on Nanomedicine 10 Years of SELDI: What Have we Learnt?
Current Proteomics The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets